9
Views
0
CrossRef citations to date
0
Altmetric
Articles

Osteopontin levels are associated with cholesterol synthesis markers in mildly hypercholesterolaemic patients

, , , , , , & show all
Pages 177-181 | Received 01 Aug 2006, Accepted 25 Jan 2007, Published online: 23 May 2017

References

  • Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Riffling SR, Denhardt DT, Glim-cher MJ, Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860–4.
  • O’Brien ER, Garvin MR, Stewart DK, Hinohara T, Simp-son JB, Schwartz SM, Giachelli CM. Osteopontin is syn-thesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atheroscle-rotic plaques. Arterioscler Thromb 1994; 14: 1648–56.
  • Golledge J, McCann M, Mangan S, Lam A, Karan M. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke 2004; 35: 1636–41.
  • Bini A, Mann KG, Kudryk BJ, Schoen FJ. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 1999; 19: 1852–61.
  • Isoda K, Kamezawa Y, Ayaori M, Kusuhara M, Tada N, Ohsuzu F. Osteopontin transgenic mice fed a high-choles-terol diet develop early fatty-streak lesions. Circulation 2003; 107: 679–81.
  • Towler DA, Bidder M, Latifi T, Coleman T, Semenkovich CF. Diet-induced diabetes activates an osteogenic gene reg-ulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem 1998; 273: 30427–34.
  • Takemoto M, Tada K, Nakatsuka K, Moriyama Y, Kazui H, Yokote K, Matsumoto T, Saito Y, Mori S. Effects of aging and hyperlipidemia on plasma osteopontin level [in Japanese]. Nippon Ronen Igakkai Zasshi 1999; 36: 799–802.
  • Bjorkhem I, Miettinen T, Reihner E, Ewerth S, Angelin B, Einarsson K. Correlation between serum levels of some cho-lesterol precursors and activity of HMG-CoA reductase in human liver. J Lipid Res 1987; 28: 1137–43.
  • Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indi-cator of whole-body cholesterol synthesis in humans. J Lipid Res 1988; 29: 1149–55.
  • Miettinen TA, Tilvis RS, Kesaniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male popu-lation. Am J Epidemiol 1990; 131: 20–31.
  • Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res 1993; 34: 1637–59.
  • Shanahan CM, Carpenter KL, Cary NR. A potential role for sterol 27-hydroxylase in atherogenesis. Atherosclerosis 2001; 154: 269–76.
  • Cali JJ, Russell DW. Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that cat-alyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem 1991; 266: 7774–8.
  • Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, Laakso J, Lehtimaki T, von Bergmann K, Lutjohann D, Laaksonen R. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005; 78: 60–8.
  • Song C, Guo Z, Ma Q, Chen Z, Liu Z, Jia H, Dang G. Sim-vastatin induces osteoblastic differentiation and inhibits adipocytic differentiation in mouse bone marrow stromal cells. Biochem Biophys Res Commun 2003; 308: 458–62.
  • Yazawa H, Zimmermann B, Asami Y, Bernimoulin JP. Sim-vastatin promotes cell metabolism, proliferation, and osteoblastic differentiation in human periodontal ligament cells. J Periodontol 2005; 76: 295–302.
  • Russell DW. Cholesterol biosynthesis and metabolism. Car-diovasc Drugs Ther 1992; 6: 103–10.
  • Ohmori R, Momiyama Y, Taniguchi H, Takahashi R, Kusuhara M, Nakamura H, Ohsuzu F. Plasma osteopontin levels are associated with the presence and extent of coro-nary artery disease. Atherosclerosis 2003; 170: 333–7.
  • Strom A, Franzen A, Wanguerud C, Knutsson AK, Heine-gard D, Hultgardh-Nilsson A. Altered vascular remodeling in osteopontin-deficient atherosclerotic mice. J Vasc Res 2004; 41: 314–22.
  • Steitz SA, Speer MY, McKee MD, Liaw L, Almeida M, Yang H, Giachelli CM. Osteopontin inhibits mineral depo-sition and promotes regression of ectopic calcification. Am J Pathol 2002; 161: 2035–46.
  • Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, Tung E, Karsenty G, Giachelli CM. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. J Exp Med 2002; 196: 1047–55.
  • Ishimura E, Okuno S, Kitatani K, Kim M, Shoji T, Nakatani T, Inaba M, Nishizawa Y Different risk factors for periph-eral vascular calcification between diabetic and non-diabetic haemodialysis patients-importance of glycaemic control. Diabetologia 2002; 45: 1446–8.
  • Matsui Y, Rittling SR, Okamoto H, Inobe M, Jia N, Shimizu T, Akino M, Sugawara T, Morimoto J, Kimura C, Kon S, Denhardt D, Kitabatake A, Uede T. Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-defi-cient mice. Arterioscler Thromb Vasc Biol 2003; 23: 1029–34.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.